tert-butyl (2-bromo-5-nitrobenzyl)carbamate | 1134559-06-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (2-bromo-5-nitrobenzyl)carbamate
• 英文别名: (2-bromo-5-nitrobenzyl)carbamic acid t-butyl ester；tert-butyl N-[(2-bromo-5-nitrophenyl)methyl]carbamate
• CAS: 1134559-06-0
• 化学式: C₁₂H₁₅BrN₂O₄
• 分子量: 331.166
• InChiKey: RDMOEKZAKVJGKK-UHFFFAOYSA-N

物化性质

• 沸点：
  446.2±35.0 °C(Predicted)
• 密度：
  1.448±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-bromo-5-nitrobenzyl)carbamate 在 盐酸 、 甲酸 、 palladium 10% on activated carbon 、 氢气 、 sodium acetate 、 palladium diacetate 、 2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 乙酸乙酯 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 70.0~160.0 ℃ 、101.33 kPa 条件下， 反应 4.0h， 生成 (2S)-N-[4-[2-methyl-7-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]-3,4-dihydro-1H-isoquinolin-3-yl]phenyl]-1-(2-phenylacetyl)pyrrolidine-2-carboxamide
  参考文献：
  名称：

  HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies

  摘要：

  In a recent disclosure,(1) we described the discovery of dimeric, prolinamide-based NS5A replication complex inhibitors exhibiting excellent potency towards an HCV genotype 1b replicon. That disclosure dealt with the SAR exploration of the peripheral region of our lead chemotype, and herein is described the SAR uncovered from a complementary effort that focused on the central core region. From this effort, the contribution of the core region to the overall topology of the pharmacophore, primarily vector orientation and planarity, was determined, with a set of analogs exhibiting < 10 nM EC50 in a genotype 1b replicon assay. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.086
• 作为产物：
  描述：

  邻溴苄胺 在 硫酸 、 potassium nitrate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 8.5h， 生成 tert-butyl (2-bromo-5-nitrobenzyl)carbamate
  参考文献：
  名称：

  钯催化的甲硅烷基醚的α-芳基化在异喹啉和菲啶的合成中

  摘要：

  通过开发两步，一锅法，构成了区域选择性的钯催化的甲硅烷基醚的Kuwajima-Urabeα-芳基化和酸介导的脱保护，环化和芳构化，已经获得了各种各样的异喹啉和菲啶。甲硅烷基醚的结构多样性导致了三类不同的异喹啉和菲啶，可以从中衍生出相关的天然产物。还证明了通过快速组装天然产物三鸟苷可实现该方法的合成效用。

  DOI：

  10.1021/acs.orglett.7b03776

文献信息

• 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES
  申请人：Clark Richard

  公开号：US20090270433A1

  公开（公告）日：2009-10-29

  A compound represented by the following general formula (1), or a salt thereof has serine protease inhibiting activity, and particularly excellent inhibiting activity against clotting factor VIIa. This compound or a salt thereof is useful as therapeutic and/or prophylactic agents for diseases associated with thrombus formation. [wherein R 1 represents hydrogen, R 2 represents optionally substituted phenyl, etc., R 3 represents optionally substituted C6-10 aryl, etc.]

  下列通式(1)所代表的化合物或其盐具有丝氨酸蛋白酶抑制活性，尤其对凝血因子VIIa有着卓越的抑制活性。该化合物或其盐可作为治疗和/或预防与血栓形成相关的疾病的药物。【其中，R1代表氢，R2代表可选取代的苯基等，R3代表可选取代的C6-10芳基等】。
• 2,3-DIHYDROIMINOISOINDOLE DERIVATIVE
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2202231A1

  公开（公告）日：2010-06-30

  A compound represented by the following general formula (1), or a salt thereof has serine protease inhibiting activity, and particularly excellent inhibiting activity against clotting factor VIIa. This compound or a salt thereof is useful as therapeutic and/or prophylactic agents for diseases associated with thrombus formation. [wherein R1 represents hydrogen, R2 represents optionally substituted phenyl, etc., R3 represents optionally substituted C6-10 aryl, etc.]

  由以下通式（1）代表的化合物或其盐具有丝氨酸蛋白酶抑制活性，尤其是对凝血因子 VIIa 具有极佳的抑制活性。该化合物或其盐类可作为治疗和/或预防血栓形成相关疾病的药物。 [其中 R1 代表氢，R2 代表任选取代的苯基等，R3 代表任选取代的 C6-10 芳基等。］
• US7807690B2
  申请人：——

  公开号：US7807690B2

  公开（公告）日：2010-10-05
• HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies
  作者：Omar D. Lopez、Van N. Nguyen、Denis R. St. Laurent、Makonen Belema、Michael H. Serrano-Wu、Jason T. Goodrich、Fukang Yang、Yuping Qiu、Amy S. Ripka、Peter T. Nower、Lourdes Valera、Mengping Liu、Donald R. O’Boyle、Jin-Hua Sun、Robert A. Fridell、Julie A. Lemm、Min Gao、Andrew C. Good、Nicholas A. Meanwell、Lawrence B. Snyder

  DOI：10.1016/j.bmcl.2012.11.086

  日期：2013.2

  In a recent disclosure,(1) we described the discovery of dimeric, prolinamide-based NS5A replication complex inhibitors exhibiting excellent potency towards an HCV genotype 1b replicon. That disclosure dealt with the SAR exploration of the peripheral region of our lead chemotype, and herein is described the SAR uncovered from a complementary effort that focused on the central core region. From this effort, the contribution of the core region to the overall topology of the pharmacophore, primarily vector orientation and planarity, was determined, with a set of analogs exhibiting < 10 nM EC50 in a genotype 1b replicon assay. (c) 2012 Elsevier Ltd. All rights reserved.
• Palladium-Catalyzed α-Arylation of Silylenol Ethers in the Synthesis of Isoquinolines and Phenanthridines
  作者：Gaurav Saini、Pravin Kumar、Gangam Srikanth Kumar、Arun Raj Kizhakkayil Mangadan、Manmohan Kapur

  DOI：10.1021/acs.orglett.7b03776

  日期：2018.1.19

  A diverse array of isoquinolines and phenanthridines have been accessed by developing a two-step, one-pot method constituting regioselective palladium-catalyzed Kuwajima–Urabe α-arylation of silylenol ethers and acid-mediated deprotection, annulation, and aromatization. Structural diversity in the silylenol ethers leads to three different classes of isoquinolines and phenanthridines from which related

  通过开发两步，一锅法，构成了区域选择性的钯催化的甲硅烷基醚的Kuwajima-Urabeα-芳基化和酸介导的脱保护，环化和芳构化，已经获得了各种各样的异喹啉和菲啶。甲硅烷基醚的结构多样性导致了三类不同的异喹啉和菲啶，可以从中衍生出相关的天然产物。还证明了通过快速组装天然产物三鸟苷可实现该方法的合成效用。